{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:45:17Z","timestamp":1764783917840},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T00:00:00Z","timestamp":1480982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00115-016-0250-6","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T12:20:29Z","timestamp":1481026829000},"page":"408-414","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Einsatz intra- bzw. subkutaner Botulinumtoxine bei Post-Zoster-Neuralgie"],"prefix":"10.1007","volume":"88","author":[{"given":"L.","family":"Halb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bornemann-Cimenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,6]]},"reference":[{"key":"250_CR1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00002508-200503000-00010","volume":"21","author":"N Allam","year":"2005","unstructured":"Allam N, Brasil-Neto JP, Brown G et al (2005) Injections of botulinum toxin type a\u00a0produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 21:182\u2013184","journal-title":"Clin J Pain"},{"key":"250_CR2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/AJP.0b013e31827a72d2","volume":"29","author":"Z Apalla","year":"2013","unstructured":"Apalla Z, Sotiriou E, Lallas A et al (2013) Botulinum toxin A\u00a0in postherpetic neuralgia: a\u00a0parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain 29:857\u2013864","journal-title":"Clin J Pain"},{"key":"250_CR3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3810\/pgm.2011.09.2469","volume":"123","author":"CE Argoff","year":"2011","unstructured":"Argoff CE (2011) Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med 123:134\u2013142","journal-title":"Postgrad Med"},{"key":"250_CR4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jpainsymman.2004.01.014","volume":"28","author":"CE Argoff","year":"2004","unstructured":"Argoff CE, Katz N, Backonja M (2004) Treatment of postherpetic neuralgia: a\u00a0review of therapeutic options. J\u00a0Pain Symptom Manage 28:396\u2013411","journal-title":"J Pain Symptom Manage"},{"key":"250_CR5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","volume":"15","author":"N Attal","year":"2016","unstructured":"Attal N, De Andrade DC, Adam F et al (2016) Safety and efficacy of repeated injections of botulinum toxin A\u00a0in peripheral neuropathic pain (BOTNEP): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet Neurol 15:555\u2013565","journal-title":"Lancet Neurol"},{"key":"250_CR6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(02)00313-1","volume":"205","author":"W Blersch","year":"2002","unstructured":"Blersch W, Schulte-Mattler WJ, Przywara S et al (2002) Botulinum toxin A\u00a0and the cutaneous nociception in humans: a\u00a0prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205:59\u201363","journal-title":"J Neurol Sci"},{"key":"250_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","volume":"2","author":"MF Brin","year":"1987","unstructured":"Brin MF, Fahn S, Moskowitz C et\u00a0al (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2:237\u2013254","journal-title":"Mov Disord"},{"key":"250_CR8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/AJP.0b013e318255c132","volume":"29","author":"WT Chen","year":"2013","unstructured":"Chen WT, Yuan RY, Chiang SC et\u00a0al (2013) OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain 29:305\u2013310","journal-title":"Clin J Pain"},{"key":"250_CR9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.juro.2007.07.120","volume":"180","author":"YC Chuang","year":"2008","unstructured":"Chuang YC, Yoshimura N, Huang CC et al (2008) Intraprostatic botulinum toxin a\u00a0injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J Urol 180:742\u2013748","journal-title":"J. Urol."},{"key":"250_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI (2013) Clinical practice: herpes zoster. N Engl J Med 369:255\u2013263","journal-title":"N Engl J Med"},{"key":"250_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","volume":"107","author":"M Cui","year":"2004","unstructured":"Cui M, Khanijou S, Rubino J et al (2004) Subcutaneous administration of botulinum toxin A\u00a0reduces formalin-induced pain. Pain 107:125\u2013133","journal-title":"Pain"},{"key":"250_CR12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1090820X11434506","volume":"32","author":"MA Doft","year":"2012","unstructured":"Doft MA, Hardy KL, Ascherman JA (2012) Treatment of hyperhidrosis with botulinum toxin. Aesthet Surg J 32:238\u2013244","journal-title":"Aesthet Surg J"},{"key":"250_CR13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuropharm.2013.02.011","volume":"70","author":"V Drinovac","year":"2013","unstructured":"Drinovac V, Bach-Rojecky L, Matak I et al (2013) Involvement of mu-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology 70:331\u2013337","journal-title":"Neuropharmacology"},{"key":"250_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","volume":"44","author":"PL Durham","year":"2004","unstructured":"Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35\u201342","journal-title":"Headache"},{"key":"250_CR15","first-page":"323","volume":"13","author":"MR Emad","year":"2011","unstructured":"Emad MR, Emad M, Taheri P (2011) The efficacy of intradermal injection of botulinum toxin in patients with post-herpetic neuralgia. Iran Red Crescent Med J 13:323\u2013327","journal-title":"Iran Red Crescent Med J"},{"key":"250_CR16","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.53.8.1850","volume":"53","author":"FJ Erbguth","year":"1999","unstructured":"Erbguth FJ, Naumann M (1999) Historical aspects of botulinum toxin: Justinus Kerner (1786\u20131862) and the \u201esausage poison\u201c. Neurology 53:1850\u20131853","journal-title":"Neurology"},{"key":"250_CR17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00016489309135834","volume":"113","author":"GM Filippi","year":"1993","unstructured":"Filippi GM, Errico P, Santarelli R et\u00a0al (1993) Botulinum A\u00a0toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400\u2013404","journal-title":"Acta Otolaryngol"},{"key":"250_CR18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S et al (2015) Pharmacotherapy for neuropathic pain in adults: a\u00a0systematic review and meta-analysis. Lancet Neurol 14:162\u2013173","journal-title":"Lancet Neurol"},{"key":"250_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","volume":"15","author":"J Frevert","year":"2015","unstructured":"Frevert J (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A\u00a0products. Drugs R D 15:1\u20139","journal-title":"Drugs R D"},{"key":"250_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00115-014-4233-1","volume":"86","author":"G Gossrau","year":"2015","unstructured":"Gossrau G (2015) Postherpetic neuralgia. Nervenarzt 86:219\u2013228","journal-title":"Nervenarzt"},{"key":"250_CR21","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.3390\/toxins8030059","volume":"8","author":"PF Hsieh","year":"2016","unstructured":"Hsieh PF, Chiu HC, Chen KC et\u00a0al (2016) Botulinum toxin A\u00a0for the treatment of overactive bladder. Toxins (Basel) 8:E59","journal-title":"Toxins (Basel)"},{"key":"250_CR22","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","volume":"371","author":"RW Johnson","year":"2014","unstructured":"Johnson RW, Rice AS (2014) Clinical practice. Postherpetic neuralgia. N Engl J Med 371:1526\u20131533","journal-title":"N Engl J Med"},{"key":"250_CR23","first-page":"452","volume":"30","author":"AW Klein","year":"2004","unstructured":"Klein AW (2004) The therapeutic potential of botulinum toxin. Dermatol Surg 30:452\u2013455","journal-title":"Dermatol Surg"},{"key":"250_CR24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0035-1571215","volume":"36","author":"R Kumar","year":"2016","unstructured":"Kumar R, Dhaliwal HP, Kukreja RV et\u00a0al (2016) The Botulinum toxin as a\u00a0therapeutic agent: molecular structure and mechanism of action in motor and sensory systems. Semin Neurol 36:10\u201319","journal-title":"Semin Neurol"},{"key":"250_CR25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/ner.12311","volume":"18","author":"D Li","year":"2015","unstructured":"Li D, Xiao L (2015) Combining botulinum toxin (A) injection with peripheral nerve stimulation in a\u00a0patient for intractable ophthalmic postherpetic neuralgia. Neuromodulation 18:769\u2013771","journal-title":"Neuromodulation"},{"key":"250_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1526-4637.2006.00100.x","volume":"7","author":"HT Liu","year":"2006","unstructured":"Liu HT, Tsai SK, Kao MC et al (2006) Botulinum toxin A\u00a0relieved neuropathic pain in a\u00a0case of post-herpetic neuralgia. Pain Med 7:89\u201391","journal-title":"Pain Med"},{"key":"250_CR27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1464-410X.2007.07312.x","volume":"101","author":"A Lucioni","year":"2008","unstructured":"Lucioni A, Bales GT, Lotan TL et\u00a0al (2008) Botulinum toxin type A\u00a0inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 101:366\u2013370","journal-title":"BJU Int"},{"key":"250_CR28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pain.2013.12.009","volume":"155","author":"MJ Marino","year":"2014","unstructured":"Marino MJ, Terashima T, Steinauer JJ et\u00a0al (2014) Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior. Pain 155:674\u2013684","journal-title":"Pain"},{"key":"250_CR29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1471-0528.2000.tb11615.x","volume":"107","author":"L Martensson","year":"2000","unstructured":"Martensson L, Nyberg K, Wallin G (2000) Subcutaneous versus intracutaneous injections of sterile water for labour analgesia: a\u00a0comparison of perceived pain during administration. BJOG 107:1248\u20131251","journal-title":"BJOG"},{"key":"250_CR30","doi-asserted-by":"crossref","first-page":"21338","DOI":"10.1016\/S0021-9258(19)36614-1","volume":"267","author":"HT Mcmahon","year":"1992","unstructured":"Mcmahon HT, Foran P, Dolly JO et al (1992) Tetanus toxin and botulinum toxins type A\u00a0and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 267:21338\u201321343","journal-title":"J Biol Chem"},{"key":"250_CR31","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","volume":"120","author":"J Meng","year":"2007","unstructured":"Meng J, Wang J, Lawrence G et al (2007) Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 120:2864\u20132874","journal-title":"J Cell Sci"},{"key":"250_CR32","doi-asserted-by":"crossref","first-page":"25665","DOI":"10.1074\/jbc.M311515200","volume":"279","author":"C Morenilla-Palao","year":"2004","unstructured":"Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N et al (2004) Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279:25665\u201325672","journal-title":"J Biol Chem"},{"key":"250_CR33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.urology.2008.02.023","volume":"72","author":"H Namazi","year":"2008","unstructured":"Namazi H (2008) Intravesical botulinum toxin A\u00a0injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis: a\u00a0molecular mechanism. Urology 72:463\u2013464 (author reply 464)","journal-title":"Urology"},{"key":"250_CR34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archderm.134.3.301","volume":"134","author":"M Naumann","year":"1998","unstructured":"Naumann M, Hofmann U, Bergmann I et\u00a0al (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134:301\u2013304","journal-title":"Arch Dermatol"},{"key":"250_CR35","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/toxins7083127","volume":"7","author":"HM Oh","year":"2015","unstructured":"Oh HM, Chung ME (2015) Botulinum toxin for neuropathic pain: a\u00a0review of the literature. Toxins (Basel) 7:3127\u20133154","journal-title":"Toxins (Basel)"},{"key":"250_CR36","first-page":"5886","volume":"7","author":"M Orsini","year":"2015","unstructured":"Orsini M, Leite MA, Chung TM et\u00a0al (2015) Botulinum neurotoxin type A\u00a0in neurology: update. Neurol Int 7:5886","journal-title":"Neurol Int"},{"key":"250_CR37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","volume":"6","author":"G Oster","year":"2005","unstructured":"Oster G, Harding G, Dukes E et al (2005) Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a\u00a0population-based survey. J Pain 6:356\u2013363","journal-title":"J Pain"},{"key":"250_CR38","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.3390\/toxins7114519","volume":"7","author":"S Pellett","year":"2015","unstructured":"Pellett S, Yaksh TL, Ramachandran R (2015) Current status and future directions of botulinum neurotoxins for targeting pain processing. Toxins (Basel) 7:4519\u20134563","journal-title":"Toxins (Basel)"},{"key":"250_CR39","first-page":"18","volume":"57","author":"RM Ponce Oliviera","year":"2013","unstructured":"Ponce Oliviera RM, Guerrero S\u00e1nchez EL, Tirado S\u00e1nchez A (2013) Botulinum toxin type A\u00a0(onabotulinum toxin A) in the management of postherpetic neuralgia. Dermatol Rev Mex 57:18\u201321","journal-title":"Dermatol Rev Mex"},{"key":"250_CR40","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/206588a0","volume":"206","author":"MJ Rand","year":"1965","unstructured":"Rand MJ, Whaler BC (1965) Impairment of sympathetic transmission by botulinum toxin. Nature 206:588\u2013591","journal-title":"Nature"},{"key":"250_CR41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","volume":"64","author":"D Ranoux","year":"2008","unstructured":"Ranoux D, Attal N, Morain F et\u00a0al (2008) Botulinum toxin type A\u00a0induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64:274\u2013283","journal-title":"Ann Neurol"},{"key":"250_CR42","first-page":"259","volume":"23","author":"C Ruiz Huete","year":"2008","unstructured":"Ruiz Huete C, Bermejo P (2008) Botulinum toxin type A\u00a0in the treatment of neuropathic pain in a\u00a0case of postherpetic neuralgia. Neurologia 23:259\u2013262","journal-title":"Neurologia"},{"key":"250_CR43","first-page":"207","volume":"19","author":"GM Sacks","year":"2013","unstructured":"Sacks GM (2013) Unmet need in the treatment of postherpetic neuralgia. Am J Manag Care 19:207\u2013213","journal-title":"Am J Manag Care"},{"key":"250_CR44","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.3390\/toxins8030065","volume":"8","author":"F Scaglione","year":"2016","unstructured":"Scaglione F (2016) Conversion ratio between Botox((R)), Dysport((R)), and Xeomin((R)) in clinical practice. Toxins (Basel) 8:E65","journal-title":"Toxins (Basel)"},{"key":"250_CR45","unstructured":"Schmutzhard E (2012) S1 Leitilinie Botulismus. Leitlinien der DGN"},{"key":"250_CR46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1254\/jphs.11060FP","volume":"118","author":"MC Shin","year":"2012","unstructured":"Shin MC, Wakita M, Xie DJ et\u00a0al (2012) Inhibition of membrane Na+ channels by A\u00a0type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J\u00a0Pharmacol Sci 118:33\u201342","journal-title":"J Pharmacol Sci"},{"key":"250_CR47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","volume":"40","author":"S Silberstein","year":"2000","unstructured":"Silberstein S, Mathew N, Saper J et\u00a0al (2000) Botulinum toxin type A\u00a0as a\u00a0migraine preventive treatment. For the BOTOX migraine clinical research group. Headache 40:445\u2013450","journal-title":"Headache"},{"key":"250_CR48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2340\/00015555-0545","volume":"89","author":"E Sotiriou","year":"2009","unstructured":"Sotiriou E, Apalla Z, Panagiotidou D et al (2009) Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol 89:214\u2013215","journal-title":"Acta Derm Venereol"},{"key":"250_CR49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbi.2013.01.088","volume":"32","author":"V Vacca","year":"2013","unstructured":"Vacca V, Marinelli S, Luvisetto S et\u00a0al (2013) Botulinum toxin A\u00a0increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and mu opioid receptor expression in neuropathic mice. Brain Behav Immun 32:40\u201350","journal-title":"Brain Behav. Immun."},{"key":"250_CR50","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/01.WNL.0000086374.92906.6A","volume":"61","author":"B Voller","year":"2003","unstructured":"Voller B, Sycha T, Gustorff B et al (2003) A\u00a0randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61:940\u2013944","journal-title":"Neurology"},{"key":"250_CR51","first-page":"31","volume":"7","author":"TJ Walker","year":"2014","unstructured":"Walker TJ, Dayan SH (2014) Comparison and overview of currently available neurotoxins. J\u00a0Clin Aesthet Dermatol 7:31\u201339","journal-title":"J Clin Aesthet Dermatol"},{"key":"250_CR52","unstructured":"Wasner G, Deutsche Gesellschaft F\u00fcr Neurologie (2012) Neuropathische Schmerzen, Diagnostik. AWMF Leitlinie 030\u2013132"},{"key":"250_CR53","first-page":"63","volume":"5","author":"F Weckx","year":"2016","unstructured":"Weckx F, Tutolo M, De Ridder D et\u00a0al (2016) The role of botulinum toxin A\u00a0in treating neurogenic bladder. Transl Androl Urol 5:63\u201371","journal-title":"Transl Androl Urol"},{"key":"250_CR54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","volume":"38","author":"MJ Welch","year":"2000","unstructured":"Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245\u2013258","journal-title":"Toxicon"},{"key":"250_CR55","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","volume":"11","author":"L Xiao","year":"2010","unstructured":"Xiao L, Mackey S, Hui H et\u00a0al (2010) Subcutaneous injection of botulinum toxin a\u00a0is beneficial in postherpetic neuralgia. Pain Med 11:1827\u20131833","journal-title":"Pain Med"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-016-0250-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T11:17:39Z","timestamp":1657970259000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-016-0250-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,6]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1007\/s00115-016-0250-6","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,6]]}}}